Kazia Therapeutics Limited (NASDAQ:KZIA), an oncology-focused biotechnology company developing thera

Kazia Therapeutics Limited (NASDAQ:KZIA) ("Kazia" or the "Company"), an oncology-foc

BTIG analyst Kambiz Yazdi maintains Kazia Therapeutics (NASDAQ:KZIA) with a Buy and raises the pr

Paxalisib Monotherapy Significantly Reduced Tumor Burden in Pre-Clinical Model of MSS/pMMR Colorecta

Preclinical Data Show Paxalisib Combined With Standard-of-Care Therapy Is Well Tolerated and Produce

Kazia Therapeutics Limited (NASDAQ:KZIA) ("Kazia" or the "Company"), an oncology-foc

Gainers Aethlon Medical (NASDAQ:AEMD) stock rose 50.7% to $3.27 during Thursday's after-market

Kazia Therapeutics Limited (NASDAQ:KZIA) ("Kazia" or the "Company"), an oncology-foc

Canaccord Genuity analyst John Newman initiates coverage on Kazia Therapeutics (NASDAQ:KZIA) with

Kazia Therapeutics Limited (NASDAQ:KZIA), an oncology-focused biotechnology company developing thera

BTIG analyst Kambiz Yazdi initiates coverage on Kazia Therapeutics (NASDAQ:KZIA) with a Buy ratin

Lake Street initiates coverage on Kazia Therapeutics (NASDAQ:KZIA) with a Buy rating and announces

Mr. Levine brings more than two decades of experience across investment banking, executive and finan

Based on continued encouraging safety, tolerability and clinical activity data observed to date, pla

Data identify nuclear PD-L1 as a previously unaddressed driver of immunotherapy resistance and metas

HC Wainwright & Co. analyst Sean Lee reiterates Kazia Therapeutics (NASDAQ:KZIA) with a Buy a

Kazia Therapeutics shared clinical update on Phase 1b study of paxalisib for late-stage metastatic T

Kazia Therapeutics (NASDAQ: KZIA), today provided a clinical update from its ongoing Phase 1b study

Shares of Byrna Technologies Inc. (NASDAQ: BYRN) rose sharply during Friday’s session after the comp

  On Thursday, 241 companies hit new 52-week lows.

  On Friday, 64 companies achieved new lows for the year.